Back to Results
First PageMeta Content
Health / Medicine / Pharmaceutical industry / Drug safety / Medical statistics / Investigational New Drug / Clinical trial / New Drug Application / Clinical research / Research / Food and Drug Administration


Appendix A: Research Plan Title of CRADA Clinical Development of Collaborator’s Proprietary Compound (Agent Name), Agent Class, as an Anti-Cancer Agent NIH CRADA Extramural Investigator/Officer(s)
Add to Reading List

Document Date: 2013-09-17 22:06:51


Open Document

File Size: 31,88 KB

Share Result on Facebook

Company

The NCI Clinical Trials Working Group / National Clinical Target Validation Laboratories / /

Continent

Europe / /

Country

United States / /

Event

FDA Phase / Person Communication and Meetings / /

IndustryTerm

correlative science technologies / pharmaceutical development / clinical trials network / Cancer Treatment / project management / pharmaceutical regulatory approval / /

MedicalCondition

cancers / tumor / cancer / disease / sensitive tumor / hematological malignancies / human tumor / solid tumors / diseases / /

MedicalTreatment

clinical Protocols / clinical Protocol / radiation / /

Movie

Standard Operating Procedure / /

Organization

DCTD’s Protocol Review Committee / Division of Cancer Treatment and Diagnosis / National Institute of Health / Investigators for Non-Clinical Studies / FDA / Investigational Drug Steering Committee / Steering Committee / /

Person

Jeffrey Abrams / IDB PI / /

Position

Investigator / Director the DCTD Division / Director the Division / general scientific background / Investigator /Officer / Co-Chair / representative / Director to the DCTD Division / /

Product

N01 / Investigational Agent / U01 / Collaborator / Investigational / /

ProvinceOrState

Indiana / /

Technology

pharmacokinetics / radiation / correlative science technologies / clinical Protocol / final Protocol / /

URL

http /

SocialTag